NGM
Nuveen Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-94,178
| Closed | -$150K | – | 3476 |
|
|
2024
Q1 | $150K | Sell |
94,178
-530,354
| -85% | -$843K | ﹤0.01% | 3220 |
|
|
2023
Q4 | $536K | Buy |
624,532
+742
| +0.1% | +$637 | ﹤0.01% | 2975 |
|
|
2023
Q3 | $667K | Sell |
623,790
-157,547
| -20% | -$169K | ﹤0.01% | 2738 |
|
|
2023
Q2 | $2.02M | Buy |
781,337
+12,453
| +2% | +$32.3K | ﹤0.01% | 2335 |
|
|
2023
Q1 | $3.14M | Buy |
768,884
+11,131
| +1% | +$45.4K | ﹤0.01% | 2143 |
|
|
2022
Q4 | $3.8M | Buy |
757,753
+18,943
| +3% | +$95.1K | ﹤0.01% | 2072 |
|
|
2022
Q3 | $9.66M | Buy |
738,810
+203,372
| +38% | +$2.66M | ﹤0.01% | 1490 |
|
|
2022
Q2 | $6.86M | Buy |
535,438
+288,412
| +117% | +$3.7M | ﹤0.01% | 1745 |
|
|
2022
Q1 | $3.75M | Sell |
247,026
-8,734
| -3% | -$133K | ﹤0.01% | 2211 |
|
|
2021
Q4 | $4.53M | Buy |
255,760
+79,824
| +45% | +$1.41M | ﹤0.01% | 2176 |
|
|
2021
Q3 | $4.05M | Buy |
175,936
+51,773
| +42% | +$1.19M | ﹤0.01% | 2327 |
|
|
2021
Q2 | $2.45M | Sell |
124,163
-48,513
| -28% | -$957K | ﹤0.01% | 2606 |
|
|
2021
Q1 | $5.02M | Buy |
172,676
+72,696
| +73% | +$2.11M | ﹤0.01% | 2172 |
|
|
2020
Q4 | $3.03M | Buy |
99,980
+6,143
| +7% | +$186K | ﹤0.01% | 2304 |
|
|
2020
Q3 | $1.49M | Sell |
93,837
-18,281
| -16% | -$291K | ﹤0.01% | 2498 |
|
|
2020
Q2 | $2.21M | Sell |
112,118
-2,320
| -2% | -$45.8K | ﹤0.01% | 2303 |
|
|
2020
Q1 | $1.41M | Sell |
114,438
-108,031
| -49% | -$1.33M | ﹤0.01% | 2358 |
|
|
2019
Q4 | $4.11M | Buy |
222,469
+198,635
| +833% | +$3.67M | ﹤0.01% | 2089 |
|
|
2019
Q3 | $330K | Buy |
23,834
+13,818
| +138% | +$191K | ﹤0.01% | 3036 |
|
|
2019
Q2 | $147K | Buy |
+10,016
| New | +$147K | ﹤0.01% | 3184 |
|